title: Bopindolol in the treatment of moderate hypertension: a dose-response study.
abstract: To determine the optimal antihypertensive dose of bopindolol, we performed a randomized double-blind study in parallel groups. After 15 days of placebo single-blind, 115 hypertensive patients received daily for 28 days one of 4 doses: 0 mg (placebo), 0.5 mg, 1.0 mg, 2.0 mg. The reduction of supine diastolic blood pressure (BP) did not exhibit the pattern of a dose-effect relationship. The effect of 0.5 mg belonged to the plateau of the dose-effect curve (P = 0.1, analysis of variance). The reduction of heart rate (HR) followed a typical dose-effect curve, with a plateau beginning with 1 mg (P = 0.02). A trend toward an increase in the incidence of side-effects with dosage was observed (P = 0.3). Thus, the optimal antihypertensive dose may be 0.5 mg or less. Previous studies not using parallel randomized groups suggested an antihypertensive dose ranging from 2 to 4 mg. This study confirms that the dose-effect curves of beta blockers on HR and BP are dissociated. The dose-effect curve of HR seems unsuitable for assessing the optimal antihypertensive dose of a beta blocker.
authors.affiliation: Unité de Pharmacologie Clinique de l'Hôpital Neurologique et Cardiologique, Lyon, France.
authors.forename: P
authors.initials: P
authors.lastname: Moleur
authors.forename: J C
authors.initials: JC
authors.lastname: Peyrieux
authors.forename: J
authors.initials: J
authors.lastname: Luciani
authors.forename: D
authors.initials: D
authors.lastname: David
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011897:Random Allocation
chemical_list: D000319:Adrenergic beta-Antagonists; D010869:Pindolol; C036007:bopindolol